“The progression of this therapeutic candidate is an example of Xanthus' commitment to the development of products that address hematological malignancies that pose an unmet medical need,” stated Richard Dean, CEO at Xanthus.
“Due to an excellent rate of accrual, we have accomplished full enrollment months earlier than we had anticipated,” stated Robert Capizzi, senior vice president at Xanthus.
The phase II study is being conducted at multiple centers in North America and enrolled patients with secondary acute myeloid leukemia. In this study, patients receive a daily dose of Xanafide for five days in combination with a standard dose of ara-C as a continuous infusion for 7 days. The primary endpoint of this study is the rate of complete remission, and secondary endpoints include duration of remission, overall survival and safety.